Sadhna Joshi

Affiliations: 
University of Toronto, Toronto, ON, Canada 
Area:
Microbiology Biology, Molecular Biology, Mental Health
Google:
"Sadhna Joshi"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Falkenhagen A, Joshi S. (2018) Genetic Strategies for HIV Treatment and Prevention. Molecular Therapy. Nucleic Acids. 13: 514-533
Falkenhagen A, Joshi S. (2018) HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins. Molecular Therapy. Nucleic Acids. 13: 347-364
Falkenhagen A, Singh J, Asad S, et al. (2017) Control of HIV Infection In Vivo Using Gene Therapy with a Secreted Entry Inhibitor. Molecular Therapy. Nucleic Acids. 9: 132-144
Falkenhagen A, Joshi S. (2017) Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FIT45. Molecular Therapy. Nucleic Acids. 7: 387-395
Falkenhagen A, Asad S, Read SE, et al. (2016) Lentiviral expression system for the purification of secreted proteins from human cell cultures. Bmc Biotechnology. 16: 66
Landry I, Zhu L, Abutarif M, et al. (2016) Model-based Phase 3 dose selection for HIV-1 attachment inhibitor prodrug BMS-663068 in HIV-1-infected patients: population pharmacokinetics/pharmacodynamics of the active moiety, BMS-626529. Antimicrobial Agents and Chemotherapy
Falkenhagen A, Ameli M, Asad S, et al. (2014) A novel gene therapy strategy using secreted multifunctional anti-HIV proteins to confer protection to gene-modified and unmodified target cells. Gene Therapy. 21: 175-87
Falkenhagen A, Ameli M, Asad S, et al. (2013) Gene therapy using a secreted single chain variable fragment targeting CCR5 to inhibit HIV infection Journal of Antivirals and Antiretrovirals. 5: 85-91
LEE-RUFF E, OSTROWSKI M, LADHA A, et al. (2010) ChemInform Abstract: Synthesis and HIV Inhibition Activity of 2′,3′-Dideoxy-3′-C-hydroxymethyl Nucleosides. Cheminform. 28: no-no
Nazari R, Joshi S. (2009) HIV-1 gene therapy at pre-integration and provirus DNA levels. Current Gene Therapy. 9: 20-5
See more...